FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2241775391> ?p ?o ?g. }

• W2241775391 endingPage "6095" @default.
• W2241775391 startingPage "6095" @default.
• W2241775391 abstract "6095 Background: Studies of noncancer patients (NCP) indicate that medication adherence is poor. Adherence among CS has not been evaluated specifically even though this is a crucial aspect of their ongoing care. Our aims were to 1) characterize adherence to CV medications in CS vs NCP, 2) compare temporal trends in adherence in these 2 cohorts, and 3) determine predictors for adherence. Methods: Using linked data from Medicare, pharmacy assistance programs, and cancer registries, we identified patients discharged from hospital for MI between 1997 and 2004. For those prescribed a statin, β-blocker, ACE inhibitor (ACEi) or all 3, we assessed adherence between CS and propensity score (PS) matched NCP. Adherence was measured using proportion of days covered (PDC), which was the number of days (NOD) of medication supplied divided by NOD in the 1st year after initial prescription. Patient was considered adherent if PDC ≥ 80%. Modified Poisson regression was used to describe trends over time and predictors of adherence. Results: In total, 964 CS and 6,923 NCP received at least 1 CV medication. Median ages were 80.3/80.2 years, 66/68% were female, and 90/91% were white, respectively. Adherence rates were suboptimal in both cohorts (18 to 45%). Between 1997 and 2004, adherence to statins and β-blockers (p<0.01 for both), but not ACEi, increased significantly among NCP (see Table). For CS over the same period, only adherence to statins improved (p<0.01). Of those prescribed all 3 medications, there was improvement in adherence among NCP (p<0.01), but not for CS (p=0.26). Comorbidities, such as heart failure and depression, were associated with poor adherence. Conclusions: Adherence to highly efficacious therapies remains low. While adherence to β-blockers and all 3 medications improved over time for NCP, this trend was not observed among CS. Medication All years P for baseline difference Year of MI P for trend P for difference in trend 1997–1998 1999–2000 2001–2002 2003–2004 Statin CS 45% 0.92 42% 51% 49% 55% < 0.01 0.24 NCP 44% 39% 47% 49% 54% < 0.01 β-blocker CS 40% 0.54 42% 40% 42% 41% 0.78 0.04 NCP 41% 39% 43% 47% 50% < 0.01 ACEi CS 38% 0.06 45% 39% 38% 39% 0.96 0.70 NCP 43% 41% 43% 45% 43% 0.11 All 3 medications CS 18% 0.21 22% 21% 20% 21% 0.26 0.02 NCP 22% 21% 24% 26% 27% < 0.01 No significant financial relationships to disclose." @default.
• W2241775391 created "2016-06-24" @default.
• W2241775391 creator A5002613498 @default.
• W2241775391 creator A5026139188 @default.
• W2241775391 creator A5026725935 @default.
• W2241775391 creator A5039850848 @default.
• W2241775391 date "2010-05-20" @default.
• W2241775391 modified "2023-09-26" @default.
• W2241775391 title "Adherence to cardiovascular (CV) medications after myocardial infarction (MI) in cancer survivors (CS)." @default.
• W2241775391 doi "https://doi.org/10.1200/jco.2010.28.15_suppl.6095" @default.
• W2241775391 hasPublicationYear "2010" @default.
• W2241775391 type Work @default.
• W2241775391 sameAs 2241775391 @default.
• W2241775391 citedByCount "0" @default.
• W2241775391 crossrefType "journal-article" @default.
• W2241775391 hasAuthorship W2241775391A5002613498 @default.
• W2241775391 hasAuthorship W2241775391A5026139188 @default.
• W2241775391 hasAuthorship W2241775391A5026725935 @default.
• W2241775391 hasAuthorship W2241775391A5039850848 @default.
• W2241775391 hasConcept C104863432 @default.
• W2241775391 hasConcept C121608353 @default.
• W2241775391 hasConcept C126322002 @default.
• W2241775391 hasConcept C17923572 @default.
• W2241775391 hasConcept C2426938 @default.
• W2241775391 hasConcept C2776839432 @default.
• W2241775391 hasConcept C2908647359 @default.
• W2241775391 hasConcept C3018553135 @default.
• W2241775391 hasConcept C500558357 @default.
• W2241775391 hasConcept C512399662 @default.
• W2241775391 hasConcept C71924100 @default.
• W2241775391 hasConcept C73269764 @default.
• W2241775391 hasConcept C98274493 @default.
• W2241775391 hasConcept C99454951 @default.
• W2241775391 hasConceptScore W2241775391C104863432 @default.
• W2241775391 hasConceptScore W2241775391C121608353 @default.
• W2241775391 hasConceptScore W2241775391C126322002 @default.
• W2241775391 hasConceptScore W2241775391C17923572 @default.
• W2241775391 hasConceptScore W2241775391C2426938 @default.
• W2241775391 hasConceptScore W2241775391C2776839432 @default.
• W2241775391 hasConceptScore W2241775391C2908647359 @default.
• W2241775391 hasConceptScore W2241775391C3018553135 @default.
• W2241775391 hasConceptScore W2241775391C500558357 @default.
• W2241775391 hasConceptScore W2241775391C512399662 @default.
• W2241775391 hasConceptScore W2241775391C71924100 @default.
• W2241775391 hasConceptScore W2241775391C73269764 @default.
• W2241775391 hasConceptScore W2241775391C98274493 @default.
• W2241775391 hasConceptScore W2241775391C99454951 @default.
• W2241775391 hasIssue "15_suppl" @default.
• W2241775391 hasLocation W22417753911 @default.
• W2241775391 hasOpenAccess W2241775391 @default.
• W2241775391 hasPrimaryLocation W22417753911 @default.
• W2241775391 hasRelatedWork W1971563841 @default.
• W2241775391 hasRelatedWork W2105039597 @default.
• W2241775391 hasRelatedWork W2146272802 @default.
• W2241775391 hasRelatedWork W2150930293 @default.
• W2241775391 hasRelatedWork W21721154 @default.
• W2241775391 hasRelatedWork W2408762584 @default.
• W2241775391 hasRelatedWork W2774072766 @default.
• W2241775391 hasRelatedWork W3185830993 @default.
• W2241775391 hasRelatedWork W4318195494 @default.
• W2241775391 hasRelatedWork W4324139986 @default.
• W2241775391 hasVolume "28" @default.
• W2241775391 isParatext "false" @default.
• W2241775391 isRetracted "false" @default.
• W2241775391 magId "2241775391" @default.
• W2241775391 workType "article" @default.